Is this solid tumors clinical trial recruiting?

Yes, this solid tumors study is currently recruiting and enrolling participants at 17 locations.

Where can I join this solid tumors trial?

This trial has 17 active sites including Los Angeles, California; Aurora, Colorado; New Haven, Connecticut and 14 more locations.

Who is eligible for this solid tumors study?

This solid tumors trial is targeting 50 participants. Detailed eligibility criteria including age requirements and medical history are listed on this page.

What phase is this solid tumors trial?

This is a PHASE1, PHASE2 clinical trial for solid tumors, sponsored by Merck Sharp & Dohme LLC. It is currently recruiting participants.

Who can participate in this Solid Tumors study?

Eligibility varies by study, but generally includes adults diagnosed with Solid Tumors who meet specific medical criteria. Complete the interest form above to learn if you may qualify.

Is the study available in Los Angeles, California?

Yes! This study has active research sites in Los Angeles, Aurora, New Haven. When you express interest, you'll be connected with the site nearest to you.

What are the benefits of joining a clinical trial for Solid Tumors?

Participants often receive: access to new treatments before they're widely available, close monitoring by medical professionals, study-related care at no cost, and the opportunity to contribute to medical research.

NCT06941272 · Merck Sharp & Dohme LLC

A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)

What this study is about

Researchers are looking for new ways to treat children with hepatoblastoma or rhabdomyosarcoma (RMS) that has relapsed or is refractory: * Hepatoblastoma is a common liver cancer in babies and very young children * RMS is a cancer that starts in muscle cells, often in a child's head and neck, bladder, treatment group$1, or legs * Relapsed means the cancer came back after treatment * Refractory means the cancer did not respond (get smaller or go away) to treatment The study treatment HER3-DXd (also known as

View original scientific description

Researchers are looking for new ways to treat children with hepatoblastoma or rhabdomyosarcoma (RMS) that has relapsed or is refractory: * Hepatoblastoma is a common liver cancer in babies and very young children * RMS is a cancer that starts in muscle cells, often in a child's head and neck, bladder, arms, or legs * Relapsed means the cancer came back after treatment * Refractory means the cancer did not respond (get smaller or go away) to treatment The study treatment HER3-DXd (also known as

Interventions

BIOLOGICAL

Patritumab Deruxtecan

IV Infusion

Primary outcome measures

Part 1: Percentage of Participants Who Experience Dose-limiting Toxicities (DLTs)

Time frame: Cycle 1 (up to approximately 21 days); each cycle is 21 days

A DLT is any of a prespecified list of adverse events (AEs) that occur during Cycle 1 (up to 21 days) if attributed to the study treatment and not attributed to any other clearly identifiable cause. The percentage of participants who experience DLTs will be reported. Each cycle is 21 days.

Part 1: Percentage of Participants Who Experience an Adverse Event (AE)

Time frame: Up to approximately 5 years

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who experience AEs will be reported.

Part 1: Percentage of Participants Who Discontinue Study Treatment Due to an AE

Time frame: Up to approximately 5 years

Part 1: Area Under the Curve (AUC) of total anti-HER3 antibody liquid chromatography-mass spectrometry (LC-MS) in plasma